文献速递慢性肾脏病肾血管病与高血压

妊娠期高血压疾病后的肾功能:一项纵向研究

Kidney Function After a Hypertensive Disorder of Pregnancy: A Longitudinal Study.
PubMed 文献 · Am J Kidney Dis · 2017-12-28

该研究基于PREVEND队列,纳入1805名无HDP女性和977名患者报告有HDP的女性,中位随访11年。HDP组CKD发生率与无HDP组相似(HR 1.04,95%CI 0.79-1.37,P=0.8),eGFR下降稍快但调整RAS阻断剂后不再显著,白蛋白尿无差异。

要点

  • 患者报告的HDP未显著增加CKD发生率。
  • HDP组eGFR下降稍快,但调整RAS阻断剂使用后差异消失。
  • 两组24小时白蛋白尿无差异,均无终末期肾病发生。

核心结论

  • 在本人群中,患者报告的HDP未 detectable 增加CKD发生率,也未显著增加肾功能下降风险。

研究设计与样本

  • PREVEND研究亚组分析,荷兰人群队列,约3年一次共5次随访。
  • 纳入无HDP女性1805例,有HDP女性977例,基线平均年龄50岁,中位随访11年。

主要发现

  • 随访期间CKD发生率在HDP组与非HDP组相似(HR 1.04,95%CI 0.79-1.37,P=0.8)。
  • eGFR从基线到随访末下降:HDP组98±15降至88±16 mL/min/1.73m2,非HDP组99±17降至91±15 mL/min/1.73m2(Pgroup<0.01,Pgroup*visit<0.05)。
  • HDP组RAS阻断剂使用率在所有访视点均更高。
  • 24小时白蛋白尿两组无差异,无人发生终末期肾病。

关键数值与推荐

  • CKD定义为eGFR<60mL/min/1.73m2和/或24小时白蛋白排泄>30mg。
  • 终末期肾病定义为接受透析或肾移植。

临床怎么用

  • 对于有HDP病史的女性,应关注肾功能变化,但不必过度解读为CKD风险显著增加。
  • RAS阻断剂的使用可能解释部分eGFR差异,临床需综合评估。

局限性

  • 无产科记录,HDP基于患者报告而非医疗记录定义。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Registry-based studies report an increased risk for end-stage kidney disease after hypertensive disorders of pregnancy (HDPs). It is unclear whether HDPs lead to an increased incidence of chronic kidney disease (CKD) and/or progression of kidney function decline. STUDY DESIGN: Subanalysis of the Prevention of Renal and Vascular Endstage Disease (PREVEND) Study, a Dutch population-based cohort with follow-up of 5 visits approximately 3 years apart. SETTING & PARTICIPANTS: Women without and with patient-reported HDPs (non-HDP, n=1,805; HDP, n=977) were identified. Mean age was 50 years at baseline and median follow-up was 11 years. FACTOR: An HDP. OUTCOMES: (1) The incidence of CKD using Cox regression and (2) the course of kidney function (estimated glomerular filtration rate [eGFR] and 24-hour albuminuria) over 5 visits using generalized estimating equation analysis adjusted for age, mean arterial pressure, and renin-angiotensin system (RAS) blockade. CKD was defined as eGFR<60mL/min/1.73m2 and/or 24-hour albuminuria with albumin excretion > 30mg, and end-stage kidney disease was defined as receiving dialysis or kidney transplantation. RESULTS: During follow-up, none of the women developed end-stage renal disease and the incidence of CKD during follow-up was similar across HDP groups (HR, 1.04; 95% CI, 0.79-1.37; P=0.8). Use of RAS blockade was higher after HDP at all visits. During a median of 11 years, we observed a decrease in eGFR in both groups, with a slightly steeper decline in the HDP group (98±15 to 88±16 vs 99±17 to 91±15mL/min/1.73m2; Pgroup<0.01, Pgroup*visit<0.05). The group effect remained significant after adjusting for mean arterial pressure, but disappeared after adjusting for RAS blockade. The 24-hour albuminuria did not differ between groups. LIMITATIONS: No obstetric records available. HDPs defined by patient report rather than health records. CONCLUSIONS: HDPs did not detectably increase the incidence of CKD. During follow-up, we observed no differences in albuminuria, but observed a marginally lower eGFR after HDP that was no longer statistically significant after adjusting for the use of RAS blockers. In this population, we were unable to identify a significant risk for kidney function decline after patient-reported HDP.

来源:Am J Kidney Dis,查看原文。版权归原作者所有。

引用

  1. Paauw ND, van der Graaf AM, Bozoglan R, et al. Kidney Function After a Hypertensive Disorder of Pregnancy: A Longitudinal Study. Am J Kidney Dis. 2017. PMID: 29289477. doi:10.1053/j.ajkd.2017.10.014

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。